1win apk

1win apk WhatsApp Rolls Out Camera Effects And Filters For iPhone Users: How To UseThe Economic and Financial Crimes Commission (EFCC) has confirmed the detention of Yahaya Bello, former governor of Kogi State, ahead of his arraignment over allegations of diverting N110 billion from the state treasury during his eight-year tenure. Dele Oyewale, EFCC spokesperson, disclosed on Tuesday evening that the former governor is currently being interrogated by investigators. According to him, Yahaya Bello will be detained and arraigned in court as soon as possible. The arraignment is scheduled for Wednesday, November 27, at the FCT High Court in Abuja. Justice Maryanne Anenih fixed the date on November 14 after Bello repeatedly ignored previous summons. The former governor has been entangled in multiple corruption cases, including money laundering charges involving N80 billion currently before the Federal High Court in Abuja. Despite a raft of court summons since April, Bello failed to appear, prompting the EFCC to file fresh charges at the FCT High Court in September. This is not the first time Bello’s dealings with the EFCC have drawn public attention. In September, he made a dramatic attempt to surrender himself at the EFCC headquarters in Abuja, accompanied by his successor, Governor Usman Ododo. However, tensions escalated later that day when EFCC operatives attempted to apprehend the former governor at the Kogi State Government Lodge in Asokoro, Abuja. The encounter reportedly turned chaotic, leading to a shootout between EFCC agents and Governor Ododo’s security personnel. Amid the commotion, he (Bello) managed to escape in the governor’s convoy. The EFCC alleges that the former governor dishonestly diverted over N110 billion in public funds while serving as governor. The charges are part of an ongoing probe into what the anti-graft agency describes as large-scale financial mismanagement in Kogi State under Bello’s administration. Bello’s Tuesday surrender at the EFCC headquarters in Abuja, without Governor Ododo’s accompaniment this time, marks a significant turning point in the long-standing corruption investigation. Security experts have described the development as a critical step in ensuring that politically exposed persons face justice without interference or undue protection. They noted that the absence of Governor Ododo, who had previously shielded Yahaya Bello from arrest, signals a shift in the dynamics of political immunity and law enforcement accountability. As Nigerians await his arraignment, the case has drawn heightened public scrutiny, with many questioning the safeguards against corruption among public officials. Experts argue that this case could serve as a litmus test for the effectiveness of the EFCC in pursuing high-profile cases, especially at a time when calls for transparency and accountability are intensifying.

None

Australia is banning social media for people under 16. Could this work elsewhere — or even there?

Fulgent Genetics chief scientific officer sells $26,773 in stockSportscaster Greg Gumbel dies from cancer at age 78Why aren’t mobile homes considered among affordable housing fixes?An online debate over foreign workers in tech shows tensions in Trump's political coalition

Jeff Bezos denies Tesla stock story and shares a laugh with Elon Musk - TESLARATIEx-FBI informant charged with lies related to Biden impeachment case indicted on tax charges

‘I don’t know if it is mental’ – Pep Guardiola explains Manchester City’s shocking collapse against FeyenoordNoneDoes the approach to treating opioid addiction need a radical overhaul?

PETALING JAYA: The much-awaited results for the Putra Brand Awards (PBA) and Putra Aria Brand Awards (PABA) for 2024 have been finalised. Billed as the “People’s Choice Awards”, the awards organising chairman and senior adviser of the Association of Accredited Advertising Agents Malaysia (4As) Datuk Johnny Mun told StarBiz the board of governors met late October to endorse the results. “The research was conducted by Ipsos, which is a global leader in market research. We have a record number of participants in the research numbering over 20,000 unique respondents with well over 65,000 responses. “This makes the PABA and PBA the most robust research event in the country and probably in Asia covering over 60 digital media platforms. “There are some surprises in the awards this year with some perennial winners being replaced by newcomers,” he added. Mun said the survey covers multiple categories, allowing consumers to voice their opinions on their favourite brands in areas ranging from food and beverage to technology and personal care. He reiterated that this comprehensive approach provides a holistic view of consumer preferences and highlights brands that have successfully established strong connections with their audience. He said the award nights for PABA are on Jan 16 and for PBA on Jan 17. Mun said the venue has shifted back to the iconic Majestic Hotel, Kuala Lumpur, to match the pomp and importance of the events. Mun is also calling marketers to buy their tables to celebrate the 15th instalment of the PBA and the third instalment of PABA to avoid disappointment. He added that for PABA, there are over 150 awards and for PBA over 160 awards. Both awards are organised by the 4As in collaboration with Star Media Group Bhd . The event is supported by the Malaysian Advertisers Association, Media Specialists Association and Malaysian Digital Association and is endorsed as Brand Champion Partner by Malaysia External Trade Development Corp or Matrade. The Star is the official news partner for the awards. The highlight for the PBA show would be the four special awards similar to last year. They are the Putra Most Enterprising Brand of the Year, Putra Malaysian Marketer of the Year, Putra Brand Personality Award and Putra Brand of the Year. There would also be the Putra Hall of Fame award, an accolade introduced in 2019 for brands that have won their respective categories for over 10 successive years. The Putra Most Enterprising Brand of the Year award reflects outstanding achievements in developing a brand that has made strong inroads into the international market via product or service innovation; is committed to comprehensive marketing and communications programmes and demonstrates a strong corporate social responsibility (CSR) commitment. The Putra Brand Personality Award celebrates an outstanding individual with creativity, perseverance and persuasion that have made significant contributions to nation building. The Putra Malaysian Marketer of the Year accolade recognises a company, team or individual exhibiting overall excellence in marketing, innovation and creativity in brand building, while challenging conventional strategies in the product sector. Lastly, the Putra Brand of the Year award is presented to the brand that best exemplifies continuous product innovation, commitment to brand building via communication and exhibits a strong sense of CSR.

Wabtec: Time To Blow Off Some SteamIRVINE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNITM assay. In a paper recently published in the journal Acta Neuropathologica Communications, DetermaCNI showed promise as a liquid biopsy method for diagnosing and profiling central nervous system tumors by measuring somatic copy number aberrations (SCNAs) in cerebrospinal fluid. For context, copy number instability (CNI) is a scientifically well-known hallmark of cancer. DetermaCNITM is a patented approach to measuring CNI for the diagnosis and monitoring of cancer. Nearly 300,000 patients in the U.S. each year face primary brain tumors or brain metastasis 1 . The current standard of care for the confirmation and classification of brain tumors often involves high-risk, highly invasive biopsy of brain tissue. Thus, a liquid biopsy method for diagnosing brain tumors could offer significant benefits over currently available methods, representing a potential $300 million U.S. market opportunity. Among the study authors were Oncocyte Chief Science Officer Ekke Schuetz and Senior R&D Director Julia Beck. "This was a proof of principle study to assess whether copy number instability could be measured in the cerebrospinal fluid of patients with brain cancer. The findings suggest that a significant number of the nearly 300,000 patients diagnosed with brain tumors every year in the U.S. could benefit from DetermaCNI,” Dr. Schuetz said. "We congratulate the research team in Frankfurt on the publication of this study in an area of high unmet need.” As noted in the paper, the gold standard for precise diagnostic classification of brain tumors requires a biopsy, with risks including limited sensitivity and failing to measure the diverse potential regions of the tumor. SCNAs were observed in the cerebrospinal fluid of ten out of the 12 patients with confirmed central nervous system cancers. SCNAs were not observed in any of the 11 patients with benign or unclear central nervous system lesions. The detection of SCNAs is highly specific for tumor-derived cell-free DNA (cfDNA). Overall, this new study demonstrates DetermaCNI's potential for providing a molecularly informed diagnosis of central nervous system cancers, mapping tumor heterogeneity, tracking tumor evolution, and surveilling tumor patients through a liquid biopsy of cerebrospinal fluid. Oncocyte believes this study validates the future clinical potential for DetermaCNI, as well as the direction of the company's research and development pipeline, which is designed to drive sustained rapid growth over the next decade. Oncocyte's mission is to democratize access to molecular diagnostic testing to improve patient outcomes. The company is investing in developing products to serve the separate verticals of organ transplant testing and oncology. Oncocyte is presently commercializing its transplant product line, which includes the VitaGraftTM and GraftAssureTM tests. It expects to commercialize its oncology assays over the next two years. _______________ 1 "Brain Metastases.” MD Anderson Cancer Center , www.mdanderson.org/cancer-types/brain-metastases.html. And "Brain Tumor Facts.” National Brain Tumor Society , 20 Feb. 2024, braintumor.org/brain-tumors/about-brain-tumors/brain-tumor-facts/. About Oncocyte Oncocyte is a diagnostics technology company. The Company's tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraftTM is a clinical blood-based dd-cfDNA solid organ transplantation monitoring test. GraftAssureTM is a research use only (RUO) blood-based solid dd-cfDNA organ transplantation monitoring test kit for decentralized use. DetermaIOTM is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNITM is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/ . For more information about our products, please visit the following web pages: VitaGraft KidneyTM - https://oncocyte.com/vitagraft-kidney/ VitaGraft Liver TM - https://oncocyte.com/vitagraft-liver/ GraftAssureTM - https://oncocyte.com/graftassure/ DetermaIOTM - https://oncocyte.com/determa-io/ DetermaCNITM - https://oncocyte.com/determa-cni/ VitaGraftTM, GraftAssureTM, DetermaIOTM, and DetermaCNITM are trademarks of Oncocyte Corporation. CONTACT: Jeff Ramson PCG Advisory (646) 863-6893 [email protected] Forward-Looking Statements Any statements that are not historical fact (including, but not limited to statements that contain words such as "will,” "believes,” "plans,” "anticipates,” "expects,” "estimates,” "may,” and similar expressions) are forward-looking statements. These statements include those pertaining to, among other things, the belief that the new study validates the future clinical potential for DetermaCNI, as well as the direction of the company's research and development pipeline, the expectation that Oncocyte will commercialize its oncology assays over the next two years, and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Oncocyte's third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients' use of any diagnostic tests Oncocyte or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the "Risk Factors” and other cautionary statements found in Oncocyte's Securities and Exchange Commission (SEC) filings, which are available from the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

FORT LAUDERDALE, Fla. (AP) — Republican senators pushed back on Sunday against criticism from Democrats that Tulsi Gabbard , Donald Trump's pick to lead U.S. intelligence services , is “compromised” by her comments supportive of Russia and secret meetings , as a congresswoman, with Syria’s president, a close ally of the Kremlin and Iran. Sen. Tammy Duckworth, an Illinois Democrat and veteran of combat missions in Iraq, said she had concerns about Tulsi Gabbard, Trump's choice to be director of national intelligence . “I think she’s compromised," Duckworth said on CNN’s “State of the Union," citing Gabbard's 2017 trip to Syria, where she held talks with Syrian President Bashar Assad. Gabbard was a Democratic House member from Hawaii at the time. “The U.S. intelligence community has identified her as having troubling relationships with America’s foes. And so my worry is that she couldn’t pass a background check,” Duckworth said. Gabbard, who said last month she is joining the Republican Party, has served in the Army National Guard for more than two decades. She was deployed to Iraq and Kuwait and, according to the Hawaii National Guard, received a Combat Medical Badge in 2005 for “participation in combat operations under enemy hostile fire in support of Operation Iraqi Freedom III." Duckworth's comments drew immediate backlash from Republicans. “For her to say ridiculous and outright dangerous words like that is wrong," Sen. Markwayne Mullin, a Republican from Oklahoma, said on CNN, challenging Duckworth to retract her words. “That’s the most dangerous thing she could say — is that a United States lieutenant colonel in the United States Army is compromised and is an asset of Russia.” In recent days, other Democrats have accused Gabbard without evidence of being a “Russian asset.” Sen. Elizabeth Warren, a Massachusetts Democrat, has claimed, without offering details, that Gabbard is in Russian President Vladimir “Putin’s pocket.” Mullin and others say the criticism from Democrats is rooted in the fact that Gabbard left their party and has become a Trump ally. Democrats say they worry that Gabbard's selection as national intelligence chief endangers ties with allies and gives Russia a win. Rep. Adam Schiff, a California Democrat just elected to the Senate, said he would not describe Gabbard as a Russian asset, but said she had “very questionable judgment.” “The problem is if our foreign allies don’t trust the head of our intelligence agencies, they’ll stop sharing information with us,” Schiff said on NBC's “Meet the Press.” Gabbard in 2022 endorsed one of Russia’s justifications for invading Ukraine : the existence of dozens of U.S.-funded biolabs working on some of the world’s nastiest pathogens. The labs are part of an international effort to control outbreaks and stop bioweapons, but Moscow claimed Ukraine was using them to create deadly bioweapons. Gabbard said she just voiced concerns about protecting the labs. Gabbard also has suggested that Russia had legitimate security concerns in deciding to invade Ukraine, given its desire to join NATO. Republican Sen. Eric Schmitt of Missouri said he thought it was “totally ridiculous” that Gabbard was being cast as a Russian asset for having different political views. “It’s insulting. It’s a slur, quite frankly. There’s no evidence that she’s a asset of another country,” he said on NBC. Sen. James Lankford, another Oklahoma Republican, acknowledged having “lots of questions” for Gabbard as the Senate considers her nomination to lead the intelligence services. Lankford said on NBC that he wants to ask Gabbard about her meeting with Assad and some of her past comments about Russia. “We want to know what the purpose was and what the direction for that was. As a member of Congress, we want to get a chance to talk about past comments that she’s made and get them into full context,” Lankford said.None

Published 5:58 pm Tuesday, November 26, 2024 By Data Skrive Wednesday’s college basketball slate includes six games with a ranked team in action. Among those contests is the Ole Miss Rebels taking on the UConn Huskies. Watch women’s college basketball, other live sports and more on Fubo. What is Fubo? Fubo is a streaming service that gives you access to your favorite live sports and shows on demand. Use our link to sign up for a free trial. Catch tons of live women’s college basketball , plus original programming, with ESPN+ or the Disney Bundle.Cal staves off Sacramento State for third straight win